PLCB2

Across TCGA pan-cancer cohorts, PLCB2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PLCB2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PLCB2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLCB2 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

KIRC, KIRP, and LUSC are the cancer types where PLCB2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLCB2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.887	<.001	12	view →
KIRP	Male	All	+1.242	<.001	11	view →
LUSC	Male	II,III,IV	−1.711	<.001	8	view →
STAD	All	II,III,IV	+1.056	<.001	7	view →
LUAD	Male	All	−0.869	<.001	7	view →
THCA	Male	II,III,IV	+0.895	.004	6	view →
HNSC	All	All	+0.386	.020	4	view →
PAAD	All	All	−1.859	.038	2	view →
UCEC	All	All	−0.725	<.001	2	view →
KICH	All	II,III,IV	−0.608	.029	2	view →
LIHC	Male	All	−0.543	.004	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PLCB2–KIRC

Open the KIRC breakdown →